SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The entire treatment process is divided into two phases: Phase I SBRT combined with
PD-1/CTLA-4 bispecific antibody (AK104) and Phase II AK104 single-agent maintenance therapy.